Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This article explores how health system factors like spending, workforce density, and radiotherapy availability influence lung cancer mortality worldwide, highlighting actionable targets for improving outcomes globally.
A propensity-matched study shows adding radiotherapy to neoadjuvant chemotherapy improves pathologic response but does not enhance survival or reduce recurrence in resected pancreatic ductal adenocarcinoma.
This review synthesizes evidence on combining lenalidomide and oral azacitidine with radiotherapy for plasmacytoma, highlighting safety, preliminary efficacy, and translational rationale in newly diagnosed and relapsed patients.
The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome
An accessible, clinician-oriented summary of the 2026 Global Chordoma Consensus—multidisciplinary, anatomy-stratified recommendations on diagnosis, surgery, high‑dose conformal radiotherapy, follow-up, and supportive care for localized chor
Emerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-ter
This review evaluates the optimal sequencing of radiotherapy and immunotherapy in advanced NSCLC, highlighting real-world evidence from the OCEANUS study favoring sequential over concurrent administration.
A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standa
The ELAN-RT trial demonstrates that hypofractionated split-course radiotherapy is non-inferior to standard fractionation for 6-month locoregional response in frail older patients, providing a less toxic alternative, though standard therapy
An umbrella review of 21 meta-analyses involving 160,000 patients confirms that prostate radiotherapy and metastasis-directed therapy significantly improve survival and progression control in oligometastatic prostate cancer, establishing a
Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while s
Recent studies on Low-Grade Endometrial Stromal Sarcoma (LG-ESS) identify cervical stromal involvement as a key prognostic marker and suggest that adjuvant radiotherapy offers no survival benefit, advocating for individualized, risk-adapted
A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a
In a randomized phase 2 trial, proton craniospinal irradiation (pCSI) significantly improved central nervous system progression‑free survival and overall survival versus involved‑field photon radiotherapy in patients with leptomeningeal met
An individual-patient data meta-analysis of 10,266 men shows nonlinear oncologic benefit from longer ADT with radiotherapy (diminishing beyond 9–12 months) but increasing other-cause mortality with long-term ADT; optimal duration should be
A multicenter propensity-matched cohort comparing adjuvant proton beam radiotherapy (PBRT) with intensity-modulated radiotherapy (IMRT) for olfactory neuroblastoma found no definitive differences in local control, recurrence-free survival,
An international multicenter cohort of 1,883 patients with radiologically growing vestibular schwannomas treated first‑line with radiotherapy showed a 10‑year tumor control rate of 76.1% (primary definition). Control estimates varied widely
A secondary analysis of the PROTECT trial reveals cribriform-positive prostate cancer significantly elevates 15-year metastasis risk, with radiotherapy plus neoadjuvant ADT reducing this risk more effectively than surgery or active monitori
This clinical trial prospectively evaluates how a 12-gene expression assay (DCIS score) guides postoperative radiotherapy decisions after breast-conserving surgery in ductal carcinoma in situ, showing tailored radiotherapy use may reduce ip
A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiot